Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

John Radford

doi:10.1056/NEJMoa1708984

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	331-344
Journal	New England Journal Of Medicine
Volume	378
DOIs	https://doi.org/10.1056/NEJMoa1708984
Publication status	Published - 25 Jan 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa1708984

Cite this

@article{e65b291e70694e319315371b5814497d,

title = "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma",

author = "John Radford",

year = "2017",

month = jan,

day = "25",

doi = "10.1056/NEJMoa1708984",

language = "English",

volume = "378",

pages = "331--344",

journal = "New England Journal Of Medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

}

TY - JOUR

T1 - Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

AU - Radford, John

PY - 2017/1/25

Y1 - 2017/1/25

UR - https://www.scopus.com/pages/publications/85041389324

U2 - 10.1056/NEJMoa1708984

DO - 10.1056/NEJMoa1708984

M3 - Article

SN - 1533-4406

VL - 378

SP - 331

EP - 344

JO - New England Journal Of Medicine

JF - New England Journal Of Medicine

ER -

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Improving survival and reducing treatment damage in Hodgkin lymphoma.

Cite this

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Impacts

Improving survival and reducing treatment damage in Hodgkin lymphoma.

Cite this